TABLE 1.
Baseline Characteristics of CALHIV at Time of First Receiving DTG at BIPAI Sites in Eastern and Southern Africa From 2017 to 2020
| Characteristic | CALHIV Receiving DTG (N = 9419) |
|---|---|
| Female (N, %) | 4791 (50.9) |
| Median age at the time of DTG in years (IQR) | 14.1 (11.3–16.78) |
| Country/site (N, %) | |
| Botswana | 1104 (11.7) |
| Eswatini | 1124 (11.9) |
| Lesotho | 1119 (11.9) |
| Malawi | 1638 (17.4) |
| Tanzania | 1703 (18.1) |
| Uganda | 2731 (29.0) |
| ART status (N, %) | |
| New ART initiations | 401 (5.5) |
| Shifted from NNRTI-based regimen | 5495 (75.1) |
| Shifted from PI-based regimen | 1424 (19.5) |
| Median time on ART before DTG in years (IQR; N = 7170) | 8.2 (5.3–11.1) |
| DTG regimen (N, %) | |
| TLD | 6856 (72.8) |
| ABC-3TC-DTG | 223 (23.7) |
| AZT-3TC-DTG | 254 (2.7) |
| Third-line ART (using DTG) | 76 (0.8) |
| History of TB disease (N, %) | 43 (0.5) |
| WHO stage (N, %) | |
| I or II | 4841 (51.4) |
| III or IV | 4577 (48.6) |
| Nutrition status (N, %) | |
| Within normal limits | 8694 (95.0) |
| Any malnutrition (mild, moderate, severe, chronic) | 459 (5.0) |
| Median follow-up time in days after receiving DTG (IQR) | 345 (208–437) |
3TC indicates lamivudine; ABC, abacavir; ART, antiretroviral therapy; AZT, zidovudine; BIPAI, Baylor International Pediatric AIDS Initiative; CALHIV, children and adolescents living with HIV; DTG - dolutegravir; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TB, tuberculosis; WHO, World Health Organization.